Target
CD30
12 abstracts
Abstract
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.Org: St. Vincent’s Hospital, The Catholic University of Korea, Haematology Unit, Royal Adelaide Hospital, Sungkyunkwan University School of Medicine,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.Org: Institut Catala d'Oncologia - Hospital Duran i Reynals, Hematology Department, Hospital 12 de Octubre,
Abstract
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.Org: Antoine-Lacassagne Cancer Center, University of Tennessee Graduate School of Medicine, Takeda Pharmaceuticals International AG,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Outcomes in pediatric relapsed/refractory anaplastic large cell lymphoma: A multi-institutional retrospective analysis.Org: Stanford University School of Medicine, Children's Hospital of The King's Daughters Surgical Group,
Abstract
Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
A population-level analysis of survival in patients with ALK+ anaplastic large cell lymphoma (ALCL) in the era of novel therapies.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Department of Translational Hematology and Oncology Research, Lerner Research Institute, Lerner Research Institute,
Abstract
Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Current Health, Dorset County Hospital, NHS Foundation Trust, Tisch Cancer Institute, Mount Sinai School of Medicine,
Abstract
Evaluating access to brentuximab in elderly patients with Hodgkin lymphoma.Org: University of Florida College of Medicine Jacksonville, University of Florida College of Pharmacy, University of Florida College of Public Health and Health Professions,
Abstract
Hodgkin lymphoma mortality trends in age subgroups from 1999 to 2020 in the United States.Org: Hackensack University Medical Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ,